Thomas Zilli

Perioperative durvalumab (12 months) with neoadjuvant EV (3 cycles) shows ‘statistically significant and clinically meaningful’ improved EFS and OS vs cystectomy alone in MIBC (like KN905 (EVP cs cystectomy)). The shorter period of EV is the major difference in trial designs. Details of efficacy and toxicity will be important. The 3rd arm, where tremelimumab was added as a triplet, did not hit OS at this stage. astrazeneca.com/media-centre/p… @OncoAlert

Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims @VanAllenLab @nikolausschultz europeanurology.com/action/showPdf…

PACE-B and HYPO-RT-PC reported cumulative incidence AND point prevalence toxicity. Both matter. Cumulative incidence captures any event over time, while point prevalence reflects ongoing morbidity. Pt information should include duration, severity and reversibility of symptoms.

Open position in our Department @IOSI @EnteOspedaliero

Really? Isn’t an editorial an opinion piece @DriesDeveltere? I hope you realise that if you used the same CTCAE scale for grading cumulative toxicity, you would have 100% G2+ indefinitely with prostatectomy…. Plenty of #radonc talk about these 2 trials cumulative AEs, which you would know if you had bothered to collaborate with one to write this editorial/opinion piece….

EV309 is a R3 (n=390) superiority study comparing EVP vs chemoradiotherapy in muscle invasive bladder cancer. It is for those ineligible or declining cystectomy. Bladder-intact Event Free Survival & OS are primary endpoints. One might expect similar results to 905/EV303, where early EVP/cystectomy outperformed cystectomy. EV309 complements EV209 (single arm trial) which tells us outcomes of the cCR patients who don’t have surgery. Is there a surgery/radiotherapy/platinum chemo free future for MIBC? clinicaltrials.gov/study/NCT07566…

Priority Editorial! When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era by Martino Pedrani et al Read the full article: buff.ly/n6uKXj0 We thank the authors for their insight. @PedraniMartino @DeGiorgiAlberto @AndreaGallina5 @UrsulaVogl @ZilliThomas @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

@matteolambe @scserendipity1 @OncoAlert @UniGenova Congratulazioni!!!

May 4, 2026 Today is a truly special day, one to remember. I am deeply honored to take on the role of Director of Medical Oncology at Galliera Hospital in Genoa. Thank you so much to all those who have supported me in reaching this important milestone ! @OncoAlert @UniGenova

Priority Editorial! When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era by Martino Pedrani et al Read the full article: buff.ly/n6uKXj0 We thank the authors for their insight. @PedraniMartino @DeGiorgiAlberto @AndreaGallina5 @UrsulaVogl @ZilliThomas @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

In prostate cancer oligoprogression, SBRT may delay next systemic therapy and possibly improve outcomes. But selection is vital @OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @OpenMedicineHQ @MedwatchKate @neerajaiims @AzadOncology @Ecastromarcos @ravikanesvaran @dmukherji @scserendipity1 @CParkMD @EAntonarakis @AttardLab @ChrisSweens1 @DrRanaMcKay @mishabeltran @ZilliThomas @AarmstrongDuke @quimmateo

Local salvage therapies alone for #ProstateCancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. ja.ma/4dhVzMS

That’s a wrap for @APCCC_Lugano 🇨🇭 Great discussions, new insights & inspiring exchanges on prostate cancer care 🎯🤝 Always a privilege to learn and connect 🌍 📸 Highlights from the meeting ⬇️ #APCCC2026 #ProstateCancer #RadOnc

Are there patients with PSA recurrence who do not need imaging and treatment? Presentation by @DrSpratticus @UHhospitals. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3QzTN0T @APCCC_Lugano

⭐ SBRT in oligometastatic CRPC — where do we stand? @OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin 🎤 Thomas Zilli closing strong 🔹 Key takeaways 👇 🔵 SBRT + SOC ➡️ May improve PFS & OS ➡️ Delays need for further systemic therapy 🔵 MDT role expanding ➡️ Valid in 1st-line CRPC ➡️ Also in repeat oligoprogression 🔵 Patient selection is everything ➡️ Modern imaging + biomarkers will refine decisions 🔵 Multidisciplinary approach ➡️ Essential to optimize outcomes ➡️ More prospective data needed 🔹 Take-home: Oligoprogression is a window of opportunity ➡️ Treat smart, delay escalation 🔥 Gran cierre de charla @ecancer @urologysummit @ravikanesvaran @urotoday @EurUrolOncol #ProstateCancer #UroOncology #RadiationOncology

⭐ Synchronous oligometastatic mHSPC — redefining disease in the PSMA era @OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin Presented by @piet_ost 🔹 Clear, structured and highly insightful talk 🔹 Key insights: • One patient → three simultaneous decisions: → systemic therapy → local prostate therapy → metastasis-directed therapy • PSMA PET is not just imaging → it is reshaping biology and prognosis • Oligometastatic disease is biologically distinct, not just low-volume • “Stage migration” is real → PSMA PET resets the goalposts • Many landmark trials were based on conventional imaging → reinterpretation needed • Intensification benefit appears concentrated in higher-risk subsets • RT to the primary still shows meaningful benefit, even in low-volume disease 🔹 Take-home: We are no longer treating “low vs high volume” — but PSMA-defined, biology-driven disease @DrSpratticus @EAntonarakis @declangmurphy @Uromigos #ProstateCancer #UroOncology #Oncology

@ZilliThomas makes elegant case @APCCC_Lugano for SBRT of oligomets in pts w castration-resistant (aka APMR) #prostatecancer - first-line and beyond! Evidence-based reminder: met-directed RT can improve OS & #radonc can play a (safe & effective) role in advanced PC. @GiulioFrancoli1 @GertMeerleer @alison_tree @nickva1 @BarbaraJereczek @piet_ost

@ZilliThomas highlights the progress made with SBRT in mCRPC. The OS benefit in ARTO by @GiulioFrancoli1 is very encouraging. All trials in this setting point in the same direction: benefit on all endpoints! #APCCC26

✨ At the @APCCC_Lugano Consensus Confer 📸 With @BarbaraJereczek , @NehaVapiwala, @VedangMurthy , @Mohamed Shelan, @DrAndrewLoblaw , @ZilliThomas , @F_lopez_campos & @GiulioFrancoli1 😄 Science, collaboration… and a quick photo break 🚀 #RadiationOncology #ProstateCancer 💪

#APCCC26 @APCCC_Lugano No one better to debate than @piet_ost Is early SRT "equivalent" to adjuvant RT in high risk/locally advanced disease? Statistically, absolutely not if you believe the RADICALS-RT data.

🚨Massive STAMPEDE reanalysis: prognosis for advanced #prostatecancer🚨 🧑‍🤝‍🧑7,000+ pts across 5 phase III RCTs @TheLancetOncol 📉PSA ≤0.2 by 24w = powerful survival signal 🦴But M1 volume + nodal status still matter 🎯PSA + imaging > PSA alone 🎯 💡Future trials: intensify or de-escalate smarter 🔗shorturl.at/Hha4u @PCFnews @PCF_Science @UrologyTimes @urotoday